Eccrine carcinoma: a rare cutaneous neoplasm
© Idrissi Serhrouchni et al.; licensee BioMed Central Ltd. 2013
Received: 9 December 2012
Accepted: 27 January 2013
Published: 4 February 2013
Eccrine carcinoma is an extremely rare malignancy of the skin with few well documented cases reported in the literature. It is frequently found on the lower extremities, and it equally affects both sexes in the sixth and seventh decade.
In our case, we present a 46- year-old female with a recurring exophytic tumor on the right lower extremity, without local extension.
The initial tumor was biopsied, excised and diagnosed as an eccrine carcinoma.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/3568051328673318.
KeywordsEccrine carcinoma Sweat gland tumor Mammary gland
Malignant cutaneous adnexal neoplasms are a large and varied group, in particular eccrine carcinoma. They are one of the most challenging areas of Dermatopathology.
Eccrine and apocrine neoplasms present a bewildering array of morphologies which often defy precise classification.
The purpose of this case is to discuss the most common problems concerning the classification of this rare neoplasm and report the aim of the immunohistochemical profiles in differential diagnosis between a primitive eccrine carcinoma of the skin and a secondary neoplasm.
The rest of the radiological examination, including radiography of the lung, abdominopelvic ultrasonography, computed tomographic thoraco-abdomino-pelvic scan, was normal.
The mammography and ultrasound examination objectified a 4 mm measuring benign cystic lesion of the left breast classified ACR 3, requiring supervision during six months.
After biopsy of the lesion, a surgical excision with clear margins was performed.
On gross examination, the tumor was 15 cm in size, bourgeoning, erythematous and heterogeneous with areas of necrosis and haemorrhage.
In contrast, the tumor cells were not reactive to cytokeratine 20, estrogen receptor, LCA, CD10, S 100 protein, HMB45, desmin, H-caldesmon, CD 99, CD 117, CD 31 and CD 34.
Based on these data, the diagnosis of primary cutaneous eccrine carcinoma was retained.
Eccrine glands are directly developed from the embryonic epidermis in the early months of fetal development. They are widely distributed almost everywhere on the skin. The topographic distribution of adnexal structures also offers insight into the logical classification of adnexal neoplasms[3, 4].
Microscopy alone is insufficient to establish eccrine lineage neoplasm because there are none specific microscopic features.
Some problems are related to the classification of sweat gland carcinomas, which are currently classified on the basis of the corresponding classification of benign sweat gland adenoma. Such an approach, however, poses several problems; for example, (1) some carcinomas have no benign counterpart and do not fit the scheme (ductal carcinoma, adenoid cystic carcinoma, and mucinous carcinoma); (2) poorly differentiated carcinomas can be diagnosed only when a contiguous adenoma is found histologically; (3) histologic classification can be very complicated because adenomas are numerous and their classification is complex; and (4) terminology includes unusual and difficult terms, deriving from the terminology used for adenomas (malignant acrospiroma, porocarcinoma, hidradenocarcinoma, malignant cylindroma, malignant spiradenoma, and syringocystadenocarcinoma)[6–9].
Recently, a classification of sweat gland carcinomas designed based on the classification of breast carcinomas has been tentatively proposed.
Finally, recent studies have classified sweat gland carcinomas into eccrine and apocrine tumors[8, 9]. In addition, no established authentic criteria are available for differentiation of an eccrine from an apocrine tumor. Moreover, both eccrine and apocrine forms seem to exist in some categories[5, 9, 11, 12].
The correct identification of the origin of tumor is of utmost importance for the determination of appropriate therapy and prognosis. Immunohistochemistry has proved to be a useful adjunct for this purpose.
The cells in the excretory coil of eccrine gland sweat express positivity for low molecular weight keratin, epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA), as well as S100 protein in the basal layer only. The myoepithelial cell layer may be highlighted by smooth muscle actin (SMA), p63 and calponin. Acrosyringeal cells stain for high molecular weight keratin and cytokeratin 14. A subpopulation of cells also expresses positivity to bcl-2. Some eccrine carcinomas are positif to estrogen and progesterone receptors wich has an important clinical implications, as affected patients may be partially treated with hormonal therapy. The Ki-67 and p53 may be used to differentiate benign from malignant lesions.
Clinically, eccrine carcinoma must be considered in the differential diagnosis of patients older than fifty years with long standing tumors in the limbs, including basal cell carcinoma (BCC), Paget’s disease, melanoma, metastatic cancer, inflammatory, lymphocytic and vascular lesions.
The histopathology of mucinous eccrine carcinoma of the skin is analogous to that of its counterpart in the breast. Consequently, it is sometimes difficult to exclude a metastatic disease[15, 18]. In a comparison between primary sweat gland tumors and metastatic breast carcinoma to skin, Busam et al.[13, 19] found that the use of antibodies against epidermal growth factor receptor strongly decorated 81% of sweat gland tumors, but only 17% of metastatic breast cancers (P=0.001). There was no significant difference between the skin tumors and metastatic breast carcinoma when antibodies against estrogen and progesterone receptors were used, but with progression of disease, androgen receptors (AR) are preserved with higher frequency than ER/PR in metastatic mammary carcinoma. In another study comparing benign, malignant primary eccrine and apocrine neoplasms to metastatic breast carcinoma, only 3.5% of these primary adnexal cancers demonstrated HER-2 positivity, whereas 10–23% of the breast carcinomas were positive[13, 20]. The authors suggested that this test may be useful in distinguishing primary skin cancers from metastatic breast cancers. Another study showed that primary cutaneous neoplasms stained strongly for p63 and CK 5/6 with high specificity, while CK 7 and 20 were not useful[15, 21]. When CK 7 was positive in the cutaneous lesions, it exhibited marked focality and a specific pattern, while metastatic breast carcinoma expressed CK 7 diffusely and did not express p63 or CK 5/6. The usefulness of CK 5/6 was again shown by Plumb et al.[15, 22]. Ivan et al.[15, 23] presented further evidence of the usefulness of p63 in the diagnosis of adnexal cancer; in their study, none of the examples of metastatic adenocarcinoma to skin stained for p63, whereas virtually all the adnexal carcinomas were positive.
These studies showed that immunohistochemistry does not distinguish cutaneous eccrine tumours from cutaneous metastases of breast carcinoma, in which case clinical and radiological correlation is critical.
Other differential diagnoses comprise neoplasms with clear cell differentiation. These include trichilemmal carcinoma, clear cell BCC and clear cell carcinomas metastatic to the skin. With respect to the latter, the dominant diagnostic considerations are metastatic clear cell carcinoma from thyroid gland and lung. The expression of TTF seen in the great majority of these cases is helpful in resolving this dilemma. Some metastatic thyroid cancers also manifest expression of thyroglobulin. Metastatic clear cell carcinoma of renal primary origin manifests a prominent stromal vascularity with hemorrhage and areas of granular necrosis typically evident in biopsy material. Clear cell squamous cell carcinoma of the cervix is a glycogen-rich cancer with intercellular bridge formation characteristic of squamous differentiation.
Eccrine carcinoma should be considered in the diagnosis of cutaneous malignant tumor with immunostaining for CK7, P63, CK5/6, estrogen and progesterone receptors.
Consent from the patient
Written informed consent was obtained from patient for publication of this case report.
Magnetic Resonance Imaging
American College of Radiology
Leukocyte Common Antigen.
- Montagna W: Embryology and anatomy of the cutaneous adnexa. J Cutan Pathol. 1984, 11: 350-351. 10.1111/j.1600-0560.1984.tb00391.x.View ArticlePubMed
- Nidal A, Khaled O, Danny G: Skin adnexal neoplasms: an approach to tumours of cutaneous sweat glands. J Clin Pathol. 2007, 60: 145-159.
- Timothy H, Calmont M: Batman and adnexal neoplasms. J Cutan Pathol. 2010, 37: 401-402. 10.1111/j.1600-0560.2010.01525.x.View Article
- Brownstein MH, Shapiro L: The sweat gland adenomas. Int J Dermatol. 1975, 14: 397-411. 10.1111/j.1365-4362.1975.tb00130.x.View ArticlePubMed
- Carmelo U, Roberto B, Milena P, Adriana S, Chiara A, Augusto G: Carcinomas of Sweat Glands. Arch Pathol Lab Med. 2001, 125: 498-505.
- Cooper PH: Carcinomas of sweat glands. Pathol Annu. 1987, 22: 83-110.PubMed
- Santa C: Sweat glands carcinomas: a comprehensive review. Semin Diagn Pathol. 1987, 4: 38-74.
- Murphy GF, Elder DE: Non-melanocytic Tumors of the Skin. 1991, Washington, DC: Armed Forces Institute of Pathology, 61-153. Atlas of Tumor Pathology; 3rd series, fascicle 1
- Requena L, Kiryu H, Ackerman AB: Neoplasms With Apocrine Differentiation. 1998, Philadelphia, Pa: Lippincott-Raven, 589-855.
- Abenoza P, Ackerman AB: Neoplasms With Eccrine Differentiation. 1990, Philadelphia, Pa: Lea and Febiger, 371-412.
- Swanson PE, Mazoujian G, Mills SE, Campbell RJ, Wick MR: Immunoreactivity for estrogen receptor protein in sweat gland tumors. Am J Surg Pathol. 1991, 15: 835-841. 10.1097/00000478-199109000-00003.View ArticlePubMed
- Ansai S, Koseki S, Hozumi Y, Kondo S: An immunohistochemical study of lysozyme, CD-15 (Leu M1), and gross cystic disease fluid protein-15 in various skin tumors: assessment of the specificity and sensitivity of markers of apocrine differentiation. Am J Dermatopathol. 1995, 17: 249-255. 10.1097/00000372-199506000-00006.View ArticlePubMed
- Vinod B, Richard A, Jinobya K: Androgen receptor expression in metastatic adenocarcinoma in females favors a breast primary. Diagn Pathol. 2006, 1: 34-10.1186/1746-1596-1-34.View Article
- Mirza I, Kloss R, Sieber SC: Malignant eccrine spiradenoma. Arch Pathol Lab Med. 2002, 126: 591-594.PubMed
- Crowson AN, Magro CM, Mihm MC: Malignant adnexal neoplasms. Mod Pathol. 2006, 19: 93-126.View Article
- Oliver C, Ashraf E, Bernard R, Armand A, Nadeem C: Eccrine porocarcinoma of the lower extremity: a case report and review of literature. World J Surg Oncol. 2011, 9: 94-10.1186/1477-7819-9-94.View Article
- Helena PS, Ventura MP, Orellana ME, Novais GA, Cheema DP, Burnier MN: Histopathological study of lesions of the caruncle: a 15-year single center review. Diagn Pathol. 2009, 4: 29-10.1186/1746-1596-4-29.View Article
- Page DL, Anderson TJ, Sakamoto G: Infiltrating carcinoma: major histological types. Diagnostic Histopathology of the Breast. Edited by: Page DL, Anderson TJ. 1987, Churchill-Livingstone: New York, 193-295.
- Busam KJ, Tan LK, Granter SR: Epidermal growth factor, estrogen, and progesterone receptor expression in primary sweat gland carcinomas and primary and metastatic mammary carcinomas. Mod Pathol. 1999, 12: 786-793.PubMed
- Hiatt KM, Pilow JL, Smoller BR: Her-2 expression in cutaneous eccrine and apocrine neoplasms. Mod Pathol. 2004, 17: 28-32. 10.1038/modpathol.3800007.View ArticlePubMed
- Qureshi HS, Ormsby AH, Lee MW: The diagnostic utility of p63, CK5/6, CK 7, and Ck 20 in distinguishing primary cutaneous adnexal neoplasms from metastatic carcinomas. Cutan Pathol. 2004, 31: 145-152. 10.1111/j.0303-6987.2004.00147.x.View Article
- Plumb SJ, Argenyi ZB, Stone MS: Cytokeratin 5/6 immunostaining in cutaneous adnexal neoplasms and metastatic adenocarcinoma. Am J Dermatopathol. 2004, 26: 447-451. 10.1097/00000372-200412000-00001.View ArticlePubMed
- Ivan D, Hafeez Diwan A, Prieto VG: Expression of p63 in primary cutaneous adnexal neoplasms and adenocarcinoma metastatic to the skin. Mod Pathol. 2005, 18: 137-142. 10.1038/modpathol.3800263.View ArticlePubMed
- Wallace ML, Longacre TA, Smoller BR: Estrogen and progesterone receptors and anti‐gross cystic disease fluid protein 15 (BRST‐2) fail to distinguish metastatic breast carcinoma from eccrine neoplasms. Mod Pathol. 1995, 8: 897-901.PubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.